The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHD™ Test for the Detection and Management of Coronary Heart Disease, which is One of the Largest Cost Centers for Public and Private Payers. CHICAGO – Cardio...
CHICAGO – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology platform which revolutionizes how patients access...
CHICAGO – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announces that the Company will showcase its groundbreaking HeartRiskTM and Actionable Clinical IntelligenceTM platforms at the American College...
Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind Technology CHICAGO – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces that the U.S. Patent and Trademark Office...
Transformative Cardiovascular Risk Management Solutions Extend Beyond Traditional Sectors to Include Federal and State Correctional Facilities, Broker and Benefits Organizations, and Risk Bearing Providers. CHICAGO – Cardio Diagnostics Holdings, Inc. (Nasdaq:...
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a retail healthcare setting on a walk-in basis. CHICAGO – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven...